Cargando…

Atezolizumab-induced subacute cerebellar ataxia in a patient with extensive-stage small cell lung cancer

Recently, immune checkpoint inhibitors (ICIs) have become the standard treatment option for patients with lung cancer, including small cell lung cancer (SCLC). ICI-induced neurological immune-related adverse events are rare and exhibit diverse clinical manifestations, often leading to missed or dela...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Chun-Chia, Tseng, Kuan-Hua, Lai, Kuan-Lin, Chiang, Chi-Lu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475224/ https://www.ncbi.nlm.nih.gov/pubmed/37667780 http://dx.doi.org/10.1177/17588359231192398

Ejemplares similares

Sun1 deficiency leads to cerebellar ataxia in mice
por: Wang, Jing-Ya, et al.
Publicado: (2015)

Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US
por: Wang, Yingcheng, et al.
Publicado: (2021)

Subacute cerebellar ataxia following respiratory symptoms of COVID-19: a case report
por: Werner, Jana, et al.
Publicado: (2021)

Prolonged Survival in a Patient With Extensive-Stage Small Cell Lung Cancer in Spite of Discontinued Immunotherapy With Atezolizumab
por: Konishi, Kazuhisa, et al.
Publicado: (2023)

Investigation of poor predictive factors in extensive stage small cell lung cancer under etoposide‐platinum‐atezolizumab treatment
por: Lim, Jeong Uk, et al.
Publicado: (2022)

First-line atezolizumab/durvalumab plus platinum–etoposide combined with radiotherapy in extensive-stage small-cell lung cancer
por: Li, Lijuan, et al.
Publicado: (2023)

Clinical outcomes of Atezolizumab Therapy for Previously-Treated Advanced-Stage Non-Small Cell Lung Cancer: A Real-World Study in Taiwan
por: Wu, Shang-Gin, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Atezolizumab Versus Durvalumab as First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer in the USA
por: Ionova, Yelena, et al.
Publicado: (2022)

Real-world evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer
por: Kim, Soo Han, et al.
Publicado: (2023)

A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization
por: Jarius, Sven, et al.
Publicado: (2010)

Treatable cerebellar ataxias()
por: K.P., Divya, et al.
Publicado: (2020)

The underpinnings of cerebellar ataxias
por: Manto, Mario
Publicado: (2022)

Phase I Study of Entinostat, Atezolizumab, Carboplatin, and Etoposide in Previously Untreated Extensive-Stage Small Cell Lung Cancer, ETCTN 10399
por: Gentzler, Ryan D, et al.
Publicado: (2023)

Clinical Recognition of Sensory Ataxia and Cerebellar Ataxia
por: Zhang, Qing, et al.
Publicado: (2021)

Neurological Erdheim–Chester Disease Manifesting with Subacute or Progressive Cerebellar Ataxia: Novel Case Series and Review of the Literature
por: Riso, Vittorio, et al.
Publicado: (2022)

Cerebellar volumetry in ataxias: Relation to ataxia severity and duration
por: Ferreira, Mónica, et al.
Publicado: (2023)

Autosomal recessive cerebellar ataxias
por: Palau, Francesc, et al.
Publicado: (2006)

An update on Spino-cerebellar ataxias
por: Mondal, Banashree, et al.
Publicado: (2013)

Metronidazole induced cerebellar ataxia
por: Hari, Aditya, et al.
Publicado: (2013)

An Unusual Etiology of Cerebellar Ataxia
por: Kaiser, Ryan Sohail, et al.
Publicado: (2020)

Milestones in genetics of cerebellar ataxias
por: Krygier, Magdalena, et al.
Publicado: (2021)

Clinical trials for cerebellar ataxia
por: Schroeder, Benjamin E., et al.
Publicado: (2022)

The inherited cerebellar ataxias: an update
por: Coarelli, Giulia, et al.
Publicado: (2022)

Rehabilitation in patients with cerebellar ataxias
por: Chien, Hsin Fen, et al.
Publicado: (2022)

Intermittent administration of atezolizumab with combined carboplatin and etoposide therapy for patients with extensive‑disease small cell lung cancer
por: Tsuda, Takeshi, et al.
Publicado: (2023)

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy
por: Kutlu, Yasin, et al.
Publicado: (2023)

The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data
por: Wang, Bi-Cheng, et al.
Publicado: (2023)

Extensive-Stage Small Cell Carcinoma Transformation From EGFR Del19-Mutant Lung Adenocarcinoma on Gefitinib at the Twelfth-Year Follow-Up Case Report
por: Kok, Victor C., et al.
Publicado: (2021)

Real‐world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive‐disease small‐cell lung cancer
por: Shiono, Ayako, et al.
Publicado: (2022)

Mitochondrial pathology in progressive cerebellar ataxia
por: Bargiela, David, et al.
Publicado: (2015)

Survival and severity in dominant cerebellar ataxias
por: Monin, Marie-Lorraine, et al.
Publicado: (2015)

Paraneoplastic cerebellar ataxia with central hypoventilation
por: Kunchok, Amy, et al.
Publicado: (2016)

Acute Cerebellar Ataxia Induced by Nivolumab
por: Kawamura, Reina, et al.
Publicado: (2017)

Autoimmune septin-5 cerebellar ataxia
por: Honorat, Josephe A., et al.
Publicado: (2018)

Autoimmune Septin-5 Cerebellar Ataxia
Publicado: (2018)

Aberrant Cerebellar Circuitry in the Spinocerebellar Ataxias
por: Robinson, Katherine J., et al.
Publicado: (2020)

Lipid Dyshomeostasis and Inherited Cerebellar Ataxia
por: Zhao, Jin, et al.
Publicado: (2022)

Neurophysiology of cerebellar ataxias and gait disorders
por: Manto, Mario, et al.
Publicado: (2023)

Immune-mediated Cerebellar Ataxia with Neurosarcoidosis
por: Mizushima, Keiichi, et al.
Publicado: (2022)

Use of Atezolizumab for Bladder and Non–Small Cell Lung Cancers
por: Moore, Kayla Faith
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_25gfcpon61mqrqgkiigq5oqit1